8-K filing — Q32 Bio Inc. (QTTB)
Filed: 2026-09-30 AccNo: 0001193125-26-408435 Size: 226 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
HC Wainwright & Co. Maintains Buy on Q32 Bio, Raises Price Target to $36
HC Wainwright & Co. analyst Joseph Pantginis maintains Q32 Bio (NASDAQ:QTTB) with a Buy and raises the price target from $13 to $36.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Q32 Bio Announces Additional 36-Week Results And Initial Findings From The 16-Week Off-Drug Period From Part B Of The SIGNAL-AA Phase 2A Clinical Trial Evaluating Bempikibart In Patients With Severe Or Very Severe AA; Clinically Meaningful Efficacy Data Observed On Primary And Key Secondary Endpoints At Week 36; Robust Durability, Including Maintenance And Deepening Of Response
Jefferies Initiates Coverage On Q32 Bio with Buy Rating, Announces Price Target of $29
Jefferies analyst Maury Raycroft initiates coverage on Q32 Bio (NASDAQ:QTTB) with a Buy rating and announces Price Target of $29.
Q32 Bio Presents Additional 36-Week Data From Its Part B Of SIGNAL-AA Phase 2a Clinical Study Of Bempikibart At European Academy Of Dermatology And Venereology Congress
Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical-stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today